

DTO-FTO trial: Small group quality improvement on prescribing and test ordering performance of general practitioners: a large scale implementation study in the South of the Netherlands

Submission date 23/08/2007	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 23/08/2007	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 18/04/2017	Condition category Other	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Mr J P Trietsch

Contact details
Maastricht University
Department of General Practice
P.O. Box 616
Maastricht
Netherlands
6200 MD
+31 (0)43 388 2877
Jasper.Trietsch@HAG.unimaas.nl

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

NTR1033

Study information

Scientific Title

DTO-FTO trial: Small group quality improvement on prescribing and test ordering performance of general practitioners: a large scale implementation study in the South of the Netherlands

Study objectives

This strategy will improve the number of tests ordered or the volume of prescribed drugs by 20% and decrease the inter-doctor variation.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics Board of the academic hospital Maastricht (azM)/Maastricht University (UM), 24/08/2006, ref: MEC 06-4-033

Study design

Multicentre cluster-randomised active-controlled parallel-group trial

Primary study design

Interventional

Secondary study design

Cluster randomised trial

Study setting(s)

GP practice

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet

Health condition(s) or problem(s) studied

Prescribing and test ordering performance of general practitioners

Interventions

All participating GP's receive feedback on their own test ordering and prescribing performance in the foregoing six months on a predefined clinical topic. The graphical comparative feedback is send to each GP individually together with an outline of current guidelines on the topic, prior to the group meeting. The feedback will lead to peer review, seeking and discussing explanations for differences, comparing own performance to the guidelines, discussing a plan for change and

discussing barriers to change. Each group discusses three clinical topics in six sessions. If the group wishes to do so, two sessions (test ordering and prescribing) can be combined into one session.

The intervention will run from September 2007 through February 2009. Please note that as of 05 /10/2007, the anticipated start date of this trial was postponed from September 2007 to December 2007.

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

1. The volume of ordered diagnostic tests and of prescribed medication
2. The inter-doctor variation in both test ordering and prescribing

Outcomes are measured at start of study (baseline), each 6 months preliminary data, after 18 months main timepoint for effect measurement, 6 and 12 months later long term effect measurement.

Secondary outcome measures

1. The quality of prescribing as defined by indicators
2. The level of functioning of the groups
3. What are the costs of implementation of the strategy?
4. Process data (attendance, altering of the meeting structure etc.)

Outcomes are measured at start of study (baseline), each 6 months preliminary data, after 18 months main timepoint for effect measurement, 6 and 12 months later long term effect measurement.

Overall study start date

01/12/2007

Completion date

01/02/2010

Eligibility**Key inclusion criteria**

Groups of General Practitioners (GPs) conjoint in pharmacotherapeutic audit groups.

Participant type(s)

Health professional

Age group

Adult

Sex

Both

Target number of participants

50 groups

Key exclusion criteria

1. Groups of over 15 GP's
2. Groups outside the provinces: Zeeland, Brabant or Limburg

Date of first enrolment

01/12/2007

Date of final enrolment

01/02/2010

Locations

Countries of recruitment

Netherlands

Study participating centre

Maastricht University

Maastricht

Netherlands

6200 MD

Sponsor information

Organisation

University Maastricht (UM) (Netherlands)

Sponsor details

Department General Practitioner Medicine

P.O. Box 616

Maastricht

Netherlands

6200 MD

+31 (0)43 388 2309

trudy.vanderweijden@hag.unimaas.nl

Sponsor type

Hospital/treatment centre

Website

<http://www.unimaas.nl/default.asp?taal=en>

ROR

<https://ror.org/02jz4aj89>

Funder(s)

Funder type

Industry

Funder Name

CZ Health Insurance Company (CZ Actief in Gezondheid) (Netherlands)

Funder Name

The Netherlands Organisation for Health Research and Development (ZonMw) (Netherlands)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	13/04/2017		Yes	No